Get started
Seaport Therapeutics, Inc.Seaport Therapeutics, Inc.Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsETFs

SEC filings and other documents


Explore the latest company documents and SEC filings from the company, including Forms 10-K, 10-Q, 8-K, and other key disclosures. Evaluate financial performance and operational updates to make more informed decisions.
2026
Earnings, Q2 FY2026
Aug 3, 2026
Advanced clinical pipeline and strong cash position following $260M IPO, despite higher Q2 losses.
Corporate presentation
Jul 31, 2026
Oral neuropsychiatric drug candidates advance with strong early data and cash runway into 2029.
Goldman Sachs 47th Annual Global Healthcare Conference 2026
Jun 10, 2026
Glyph platform advances neuropsychiatric drugs with key clinical milestones and strong funding.
Earnings, Q1 FY2026
Jun 8, 2026
Clinical progress and $260M IPO extend cash runway into 2029 amid increased R&D investment.
Corporate presentation
Jun 6, 2026
Oral neuropsychiatric drug candidates show strong clinical promise and funding through 2029.